Current and future therapeutic targets in COPD: insights from clinical trials - Amsterdam 2025

Chronic obstructive pulmonary disease and type 2 inflammation: is it really a treatable trait?

Chair(s): Francesca Polverino, Augusta Beech

Session type: Symposium

Current and future therapeutic targets in COPD: insights from clinical trials

Mona Bafadhel

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

COPD: pathobiological features supporting the case for a T2 trait

Carlos Cabrera Lopez

Replay

Slides

Eosinophilic COPD: is it just asthma? Evidence from the clinic and trials

Johann Christian Virchow

Replay

Slides

Beyond eosinophils and T2: conventional culprits and targets in COPD biology

Hsiao-chi Chuang

Replay

Slides

Current and future therapeutic targets in COPD: insights from clinical trials

Mona Bafadhel

Replay

Slides

Discussion and Q&A

Replay

Session aims

to discuss the recent findings on type 2 (T2) inflammation in chronic obstructive pulmonary disease (COPD); to explore the future of therapeutic development of T2 immune modulators in COPD.

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}